Supplementary Table 21. Univariate analysis: predictors of infliximab failure in Korean patients with ulcerative colitis

Variables	Hazard ratio[a]	P value[b]
Male	0.99	0.517
Age at diagnosis (> 40 years)	1.36	0.521
Age at the initiation of IFX (> 40 years)	1.49	0.190
Disease duration prior to the initiation of IFX (< 3 years)	1.21	0.217
Indication for IFX (steroid refractoriness)	1.47	0.047
Disease extent at the initiation of IFX (extensive colitis)	1.17	0.746
Disease activity at the initiation of IFX (severe, Mayo score ≥ 11 points)[c]	1.42	0.009
Deep colonic ulceration at the initiation of IFX[d]	0.95	0.881
History of CMV colitis within 3 months prior to the initiation of IFX	1.57	0.005
History of UC-related hospitalization within 3 months prior to the initiation of IFX	1.37	0.088
Intolerant or refractory to thiopurines prior to the initiation of IFX	1.21	0.382
pANCA positivity	0.91	0.499
Leukocytosis at baseline (> 10^4/μL)	0.85	0.610
Anemia at baseline (< 13 g/dL in male, < 12 g/dL in female)	0.91	0.914
Thrombocytosis at baseline (> 3.5×10^6/μL)	0.69	0.173
Elevated ESR at baseline (> 9 mm/hr in male, > 20 mm/hr in female)	0.65	0.131
Elevated CRP level at baseline (≥ 0.6 mg/dL)	1.18	0.516
Hypoalbuminemia at baseline (< 3.4 mg/dL)	1.11	0.327

3

Current smoker at diagnosis	0.67	0.324
~~Previous history of appendectomy[§]~~	~~1.62~~	~~0.661~~

IFX, infliximab; CMV, cytomegalovirus; pANCA, perinuclear antineutrophil cytoplasmic antibody; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein

[a]Cox proportional hazards model

[b]Wilcoxon test

[c]Mayo scores at the initiation of IFX were missing for two study patients, and the univariate analysis for this variable was performed among the remaining 193 patients.

[d]In one study patient, ~~both~~ the baseline endoscopic findings at the initiation of IFX w~~ere~~as unavailable ~~and a previous history of appendectomy was unknown~~;, and the univariate analys~~e~~is for th~~ese~~is ~~two~~ variable~~s~~ w~~ere~~as conducted among the remaining 194 patients.